aTyr Pharma (LIFE) Getting Somewhat Favorable News Coverage, Study Shows

Press coverage about aTyr Pharma (NASDAQ:LIFE) has trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. aTyr Pharma earned a news impact score of 0.14 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.8047876615765 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

A number of research analysts recently issued reports on the company. Zacks Investment Research downgraded aTyr Pharma from a “buy” rating to a “hold” rating and set a $5.25 price objective for the company. in a report on Thursday, September 28th. Piper Jaffray Companies assumed coverage on aTyr Pharma in a research note on Thursday, September 7th. They issued an “overweight” rating and a $7.00 price target for the company. BMO Capital Markets set a $4.00 price target on aTyr Pharma and gave the company a “hold” rating in a research note on Tuesday, August 15th. Finally, ValuEngine downgraded aTyr Pharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 6th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $4.62.

aTyr Pharma (NASDAQ:LIFE) last released its earnings results on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.06.

In other aTyr Pharma news, Director Paul Schimmel bought 94,336 shares of aTyr Pharma stock in a transaction dated Thursday, August 31st. The stock was bought at an average cost of $2.65 per share, with a total value of $249,990.40. Following the completion of the acquisition, the director now directly owns 40,440 shares in the company, valued at approximately $107,166. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO John Mendlein bought 37,736 shares of aTyr Pharma stock in a transaction dated Thursday, August 31st. The stock was acquired at an average cost of $2.65 per share, with a total value of $100,000.40. The disclosure for this purchase can be found here. Corporate insiders own 33.30% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was posted by Stock Observer and is owned by of Stock Observer. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.thestockobserver.com/2017/10/13/atyr-pharma-life-getting-somewhat-favorable-news-coverage-study-shows.html.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Insider Buying and Selling by Quarter for aTyr Pharma (NASDAQ:LIFE)

Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply